InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,495.52
(
0.45%
)
US TECH 100
18,346.40
(
0.00%
)
Dow Jones
40,736.96
(
-0.23%
)
Brent Oil
70.07
(
0.77%
)
Bitcoin
56,584.03
(
-1.87%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 312

Tuesday, 08/21/2018 2:21:22 PM

Tuesday, August 21, 2018 2:21:22 PM

Post# of 438
SRRK is a 5/18 IPO focusing on localized protein growth factors.

Other biotech firms focusing on protein growth factors do so in a systemic way that does not control side effects well.

The lead program is a selective inhibitor of Myostatin activation aimed at reversing/preventing spinal muscle atrophy.

Cash runway extends into 2020 but dilution is likely in 2019.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up